
NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..
Think overactive bladder is just a nuisance? Many studies prove that it severely diminishes quality of life, including the ability to work productively. The cost is in the billions.






